Bioreactor for blood product production

Doran, Michael R., Aird, Ian Alexander, Marturana, Flavia, Timmins, Nicholas, Atkinson, Kerry and Nielsen, Lars K. (2012) Bioreactor for blood product production. Cell Transplantation, 21 6: 1235-1244. doi:10.3727/096368911X627363

Author Doran, Michael R.
Aird, Ian Alexander
Marturana, Flavia
Timmins, Nicholas
Atkinson, Kerry
Nielsen, Lars K.
Title Bioreactor for blood product production
Journal name Cell Transplantation   Check publisher's open access policy
ISSN 0963-6897
Publication date 2012
Sub-type Article (original research)
DOI 10.3727/096368911X627363
Open Access Status
Volume 21
Issue 6
Start page 1235
End page 1244
Total pages 10
Place of publication Putnam Valley, NY, United States
Publisher Cognizant Communication Corporation
Collection year 2013
Language eng
Formatted abstract
The feasibility of ex vivo blood production is limited by both biological and engineering challenges. From an engineering perspective, these challenges include the significant volumes required to generate even a single unit of a blood product, as well as the correspondingly high protein consumption required for such large volume cultures. Membrane bioreactors, such as hollow fiber bioreactors (HFBRs), enable cell densities approximately 100-fold greater than traditional culture systems and therefore may enable a significant reduction in culture working volumes. As cultured cells, and larger molecules, are retained within a fraction of the system volume, via a semipermeable membrane it may be possible to reduce protein consumption by limiting supplementation to only this fraction. Typically, HFBRs are complex perfusion systems having total volumes incompatible with bench scale screening and optimization of stem cell-based cultures. In this article we describe the use of a simplified HFBR system to assess the feasibility of this technology to produce blood products from umbilical cord blood-derived CD34+ hematopoietic stem progenitor cells (HSPCs). Unlike conventional HFBR systems used for protein manufacture, where cells are cultured in the extracapillary space, we have cultured cells in the intracapillary space, which is likely more compatible with the large-scale production of blood cell suspension cultures. Using this platform we direct HSPCs down the myeloid lineage, while targeting a 100-fold increase in cell density and the use of protein-free bulk medium. Our results demonstrate the potential of this system to deliver high cell densities, even in the absence of protein supplementation of the bulk medium.
Keyword Blood product
Hematopoietic stem cell
Neutrophil (culture)
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2013 Collection
Australian Institute for Bioengineering and Nanotechnology Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 4 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 4 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 20 Oct 2011, 15:55:57 EST by Ms Flavia Marturana on behalf of Aust Institute for Bioengineering & Nanotechnology